Published in Br J Pharmacol on November 01, 1996
Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol (2011) 1.10
Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT₃ receptor antagonists. Cancer Chemother Pharmacol (2010) 1.05
Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics. Br J Cancer (2003) 0.83
Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting. Pharmaceuticals (Basel) (2010) 0.79
Profile of Antiemetic Activity of Netupitant Alone or in Combination with Palonosetron and Dexamethasone in Ferrets and Suncus murinus (House Musk Shrew). Front Pharmacol (2016) 0.76
Evaluating the various phases of cisplatin-induced emesis in rats. Oncol Lett (2014) 0.75
Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med (1990) 3.05
Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J Pharmacol Exp Ther (1993) 1.26
The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol (1995) 1.18
Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994. Neuropharmacology (1994) 0.99
An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br J Pharmacol (1996) 0.99
Substance P-induced inflammatory responses in guinea-pig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators. Br J Pharmacol (1995) 0.96
Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol (1993) 0.91
The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret. Neuropharmacology (1996) 0.91
Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer (1993) 0.90
The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol (1995) 0.89
Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination. Oncology (1993) 0.87
Enantiospecific inhibition of emesis induced by nicotine in the house musk shrew (Suncus murinus) by the neurokinin1 (NK1) receptor antagonist CP-99,994. Neuropharmacology (1995) 0.85
Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology (1993) 0.85
The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist. Br J Pharmacol (1995) 0.84
Potential for combination therapy with the new antiserotonergic agents. Eur J Cancer (1993) 0.79
Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin. J Physiol (1983) 2.42
Antagonism of the hyperactivity induced by dopamine applied intracerebrally to the nucleus accumbens septi by typical neuroleptics and by clozapine, sulpiride and thioridazine. Eur J Pharmacol (1976) 2.14
Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol (1988) 1.96
The effects of substance P on histamine and 5-hydroxytryptamine release in the rat. J Physiol (1982) 1.88
5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology (1986) 1.78
Actions of dopaminergic agonists on motor function. Adv Neurol (1975) 1.72
Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol Biochem Behav (1989) 1.64
Nomifensine: a potent dopaminergic agonist of antiparkinson potential. Psychopharmacologia (1975) 1.63
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer (2003) 1.48
5-Hydroxytryptamine receptor antagonism by metoclopramide and ICS 205-930 in the guinea-pig leads to enhancement of contractions of stomach muscle strips induced by electrical field stimulation and facilitation of gastric emptying in-vivo. J Pharm Pharmacol (1985) 1.46
Stereotyped and circling behaviour induced by dopaminergic agonists after lesions of the midbrain raphe nuclei. Eur J Pharmacol (1974) 1.36
Receptors mediating tachykinin-induced contractile responses in guinea-pig trachea. Br J Pharmacol (1991) 1.33
Release of acetylcholine and 14 C-glycine from the cat spinal cord in vivo. Br J Pharmacol (1971) 1.30
Receptor-selective, peptidase-resistant agonists at neurokinin NK-1 and NK-2 receptors: new tools for investigating neurokinin function. Neuropeptides (1991) 1.24
Neuroleptic and non-neuroleptic catalepsy. Arzneimittelforschung (1973) 1.20
Stereotypic and anticataleptic activities of amphetamine after intracerebral injections. Eur J Pharmacol (1972) 1.19
Neuropharmacology of emesis in relation to clinical response. Br J Cancer Suppl (1992) 1.18
Pharmacological characterization of 5-hydroxytryptamine-induced hyperpolarization of the rat superior cervical ganglion. Br J Pharmacol (1987) 1.18
Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology (1975) 1.17
Antiemetic properties of the 5HT3-receptor antagonist, GR38032F. Cancer Treat Rev (1987) 1.17
Neuroleptic antagonism of dyskinetic phenomena. Eur J Pharmacol (1976) 1.16
Identification of 5-HT3 recognition sites in human brain tissue using [3H]zacopride. J Pharm Pharmacol (1988) 1.16
Temperature modulation of alpha- and beta-adrenoceptors in the isolated frog heart. Br J Pharmacol (1970) 1.15
5-Hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders. Scand J Gastroenterol (1990) 1.14
The 6-hydroxydopamine rotational model for the detection of dopamine agonist activity: reliability of effect from different locations of 6-hydroxydopamine. J Pharm Pharmacol (1975) 1.13
The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol Biochem Behav (1989) 1.13
Potent and highly selective neurokinin antagonists. J Med Chem (1990) 1.13
A role for the amygdala in the development of the cataleptic and stereotypic actions of the narcotic agonists and antagonists in the rat. Psychopharmacologia (1974) 1.11
The potential anxiolytic activity of GR38032F, a 5-HT3-receptor antagonist. Br J Pharmacol (1988) 1.11
Circling behaviour produced by asymmetric medial raphé nuclei lesions in rats. J Pharm Pharmacol (1976) 1.10
Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain. Eur J Pharmacol (1987) 1.09
The behavioural effects of dopamine applied intracerebrally to areas of the mesolimbic system. Eur J Pharmacol (1975) 1.08
5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature (1989) 1.08
Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res (1989) 1.08
Zacopride, a potent 5-HT3 antagonist. J Pharm Pharmacol (1988) 1.07
The psychopharmacology of 5-HT3 receptors. Pharmacol Ther (1990) 1.06
Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav (1991) 1.05
5-HT4 receptor mediated facilitation of the emptying phase of the peristaltic reflex in the guinea-pig isolated ileum. Br J Pharmacol (1993) 1.03
A study of [D-Pro2, D-Phe7, D-Trp9]-substance P and [D-Trp7,9]-substance P as tachykinin partial agonists in the rat colon. Br J Pharmacol (1984) 1.03
Catalepsy and circling behaviour after intracerebral injections of neuroleptic, cholinergic and anticholinergic agents into the caudate-putamen, globus pallidus and substantia nigra of rat brain. Neuropharmacology (1972) 1.02
Evidence for a 5-HT3 receptor involvement in the facilitation of peristalsis on mucosal application of 5-HT in the guinea pig isolated ileum. Br J Pharmacol (1997) 1.01
Characterisation and autoradiographic localisation of 5-HT3 receptor recognition sites identified with [3H]-(S)-zacopride in the forebrain of the rat. Neuropharmacology (1990) 1.01
Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol (1987) 1.01
Serotoninergic modulation of the dopamine response from the nucleus accumbens. J Pharm Pharmacol (1976) 1.00
Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical antipsychotic effect? Psychopharmacologia (1973) 1.00
The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig. Br J Pharmacol (1987) 1.00
Early histological features of small intestinal injury induced by indomethacin. Aliment Pharmacol Ther (1993) 1.00
An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br J Pharmacol (1996) 0.99
Serotonergic involvement with the stereotypy/catalepsy induced by morphine-like agents in the rat. J Pharm Pharmacol (1975) 0.98
Identification and characterisation of 5-hydroxytryptamine 3 recognition sites in human brain tissue. J Neurochem (1989) 0.98
Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur J Pharmacol (1978) 0.98
A comparison of circling models for the detection of antiparkinson activity. Psychopharmacologia (1975) 0.98
Evolution of a novel series of [(N,N-dimethylamino)propyl]- and piperazinylbenzanilides as the first selective 5-HT1D antagonists. J Med Chem (1994) 0.98
Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther (2006) 0.97
Design of agents for stimulation of neostriatal dopaminergic mechanisms. J Pharm Pharmacol (1974) 0.97
Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol Biochem Behav (1990) 0.96
Relative activities of substance P-related peptides in the guinea-pig ileum and rat parotid gland, in vitro. Br J Pharmacol (1982) 0.96
Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol (1991) 0.96
Toxic effects of solstitialin A 13-acetate and cynaropicrin from Centaurea solstitialis L. (Asteraceae) in cell cultures of foetal rat brain. Neuropharmacology (1992) 0.96
Reserpine, para-chlorophenylalanine and fenfluramine antagonise cisplatin-induced emesis in the ferret. Neuropharmacology (1988) 0.96
SCH 23390 is a very potent and selective antagonist at vascular dopamine receptors. Eur J Pharmacol (1984) 0.95
Highly potent and selective heptapeptide antagonists of the neurokinin NK-2 receptor. J Med Chem (1992) 0.95
Interaction of neurotensin with the substance P receptor mediating histamine release from rat mast cells and the flare in human skin. Br J Pharmacol (1982) 0.95
[3H]zacopride: ligand for the identification of 5-HT3 recognition sites. J Pharm Pharmacol (1988) 0.93
Catecholamines act as alpha 2-adrenoceptors to cause contraction of circular smooth muscle of guinea-pig stomach. J Pharm Pharmacol (1982) 0.93
Zacopride: anxiolytic profile in rodent and primate models of anxiety. J Pharm Pharmacol (1988) 0.93
Modification of the behavioural changes induced by amphetamine in the rat by lesions in the caudate nucleus, the caudate-putamen and globus pallidus. Neuropharmacology (1972) 0.93
Alternative approaches to analgesia: baclofen as a model compound. Br J Pharmacol (1975) 0.93
An examination of the pharmacology of two substance P antagonists and the evidence for tachykinin receptor subtypes. Br J Pharmacol (1986) 0.93
Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs. Neuropharmacology (1987) 0.92
Neuropharmacological studies on the neuroleptic potential of domperidone (R33812). J Pharm Pharmacol (1979) 0.91
Anxiolytic-like action of DuP753, a non-peptide angiotensin II receptor antagonist. Neuroreport (1990) 0.91
Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain. Trends Pharmacol Sci (1990) 0.91
The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret. Neuropharmacology (1996) 0.91
Characterisation of the mechanisms for hyperactivity induction from the nucleus accumbens by phenylethylamine derivatives. Psychopharmacology (Berl) (1976) 0.90
Sites of action of ondansetron to inhibit withdrawal from drugs of abuse. Pharmacol Biochem Behav (1990) 0.90
Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology (1994) 0.90
Hyperactivity response to apomorphine and amphetamine in the mouse: the importance of the nucleus accumbens and caudate-putamen. J Pharm Pharmacol (1979) 0.90
Cognitive enhancing actions of DuP 753 detected in a mouse habituation paradigm. Neuroreport (1991) 0.90
The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol (1995) 0.89
Fluphenazine, ICS 205-930 and dl-fenfluramine differentially antagonise drug-induced emesis in the ferret. Neuropharmacology (1990) 0.89
Variables of movement amplitude and frequency in the development of motion sickness in Suncus murinus. Pharmacol Biochem Behav (1999) 0.88
Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat. Br J Pharmacol (1990) 0.88
Pharmacological characterization of the 5-hydroxytryptamine receptor mediating relaxation in the rat isolated ileum. Br J Pharmacol (1996) 0.88
Actions of sulpiride and tiapride in a simple model of anxiety in mice. Neuropharmacology (1987) 0.88
Angiotensin-converting enzyme inhibition, angiotensin, and cognition. J Cardiovasc Pharmacol (1992) 0.88
Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition. Brain Res (1990) 0.87
Specific asymmetric behavior induced by the direct chemical stimulation of neostriatal dopaminergic mechanisms. Naunyn Schmiedebergs Arch Pharmacol (1974) 0.87
The substantia nigra and stereotyped behaviour. Eur J Pharmacol (1972) 0.87
Dyskinetic phenomena caused by the intrastriatal injection of phenylethylamine, phenylpiperazine, tetrahydroisoquinoline and tetrahydronaphthalene derivatives in the guinea pig. Eur J Pharmacol (1975) 0.87
Dissociation of stereotyped biting responses and oro-bucco-lingual dyskinesias. Eur J Pharmacol (1976) 0.87
Characterisation of the mechanisms by which purported dopamine agonists reduce spontaneous locomotor activity of mice. Eur J Pharmacol (1981) 0.87
Anxiolytic potential of 5-HT3 receptor antagonists. Pharmacol Toxicol (1992) 0.87
The differential activities of R (+)- and S(-)-zacopride as 5-HT3 receptor antagonists. Pharmacol Biochem Behav (1990) 0.87
The actions of fentanyl to inhibit drug-induced emesis. Neuropharmacology (1991) 0.86
Agonist interactions with 5-HT3 receptor recognition sites in the rat entorhinal cortex labelled by structurally diverse radioligands. Br J Pharmacol (1992) 0.86
Differences in the nature of the stereotyped behaviour induced by aporphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas. Eur J Pharmacol (1975) 0.86
The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates. Pharmacol Biochem Behav (1990) 0.86
The substance P receptor on rat mast cells and in human skin. Agents Actions (1984) 0.85
The site and mode of action of ET495 for the mediation of stereotyped behaviour in the rat. Naunyn Schmiedebergs Arch Pharmacol (1973) 0.85